ASPYRE-Lung enables the detection of key genetic mutations from tissue or liquid biopsies. Credit: National Cancer Institute / Unsplash.

Biofidelity has raised $23m in a heavily oversubscribed Series A+ funding round for the upcoming launch of its first commercial diagnostic assay, ASPYRE-Lung.

Octopus Ventures led the round, which was backed by SBI Investment along with existing investors.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Developed based on the company’s molecular technology, the assay enables the detection of key genetic mutations from tissue or liquid biopsies.

This simplifies and accelerates the detection of genomic biomarkers.

Biofidelity developed the new technology to run on existing PCR machines, the instruments that are used for Covid-19 tests.

See Also:

This makes the comprehensive analysis of genomic biomarkers accessible for patients worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The analysis provided by the assay will help physicians identify patients who may benefit from cancer therapies.

This will lead to better outcomes for patients, reduced side effects and improved survival rates.

Biofidelity CEO Dr Barnaby Balmforth said: “Our mission is to ensure that all patients diagnosed with cancer have access to the genomic information they need to receive the best possible treatment.

“This financing is an important step towards making this vision a reality, enabling us to launch our revolutionary technology and to make comprehensive biomarker testing faster, more affordable and more accessible than ever before.”

The company stated that while its initial focus is on non-small cell lung cancer (NSCLC), it also aims to expand the new technology to broad application across the cancer testing market.

In May 2020, Biofidelity raised $12m in a Series A financing round that was supported by Agilent Technologies, BlueYard Capital and Longwall Ventures.

The latest round brings Biofidelity’s total funding raised to $36m.